{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T08:14:11Z","timestamp":1781165651979,"version":"3.54.1"},"reference-count":29,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cephalalgia"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Comparative evaluations of preventive migraine treatments can help inform clinical decision making for managing migraine in clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An anchored matching-adjusted indirect comparison analysis was conducted using pooled participant-level data from two phase 3 atogepant trials (ADVANCE and PROGRESS) and one phase 2\/3 rimegepant trial (BHV3000-305) to evaluate the relative efficacy and safety\/tolerability of atogepant and rimegepant as preventive migraine treatments. Participants receiving atogepant 60\u2009mg once daily, rimegepant orally disintegrating tablet 75\u2009mg once every other day, and placebo were included. Only participants meeting the BHV3000-305 inclusion\/exclusion criteria were analyzed: \u22656 monthly migraine days and \u226418 monthly headache days at baseline. The primary efficacy assessment of interest was change in monthly migraine days across weeks 1\u201312.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There were 252 participants in the atogepant group and 348 in the rimegepant group. Across weeks 1\u201312, atogepant 60\u2009mg demonstrated a significantly greater reduction in mean monthly migraine days compared with rimegepant 75\u2009mg (mean difference [95% CI]: \u22121.65 [\u22122.49, \u22120.81]; p\u2009&lt;\u20090.001). Both atogepant and rimegepant demonstrated similar safety\/tolerability profiles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this matching-adjusted indirect comparison analysis, oral atogepant 60\u2009mg once daily demonstrated a significantly greater reduction in monthly migraine days compared with rimegepant 75\u2009mg orally disintegrating tablet once every other day.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03331024241235156","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T03:45:13Z","timestamp":1709005513000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":19,"title":["Comparative efficacy, quality of life, safety, and tolerability of atogepant and rimegepant in migraine prevention: A matching-adjusted indirect comparison analysis"],"prefix":"10.1177","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1513-2113","authenticated-orcid":false,"given":"Cristina","family":"Tassorelli","sequence":"first","affiliation":[{"name":"Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy"},{"name":"Headache Science & Neurorehabilitation Centre, IRCCS C. Mondino Foundation and University of Pavia, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kateryna","family":"Onishchenko","sequence":"additional","affiliation":[{"name":"AbbVie, London, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi B.","family":"Halker Singh","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Scottsdale, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Duan","sequence":"additional","affiliation":[{"name":"AbbVie, North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Dupont-Benjamin","sequence":"additional","affiliation":[{"name":"AbbVie, Courbevoie, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Hemstock","sequence":"additional","affiliation":[{"name":"Lumanity, Sheffield, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0309-0197","authenticated-orcid":false,"given":"Corey","family":"Voller","sequence":"additional","affiliation":[{"name":"Lumanity, London, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"McAllister","sequence":"additional","affiliation":[{"name":"New England Institute for Neurology & Headache, Stamford, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie J.","family":"Nahas","sequence":"additional","affiliation":[{"name":"Department of Neurology, Thomas Jefferson University, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranav","family":"Gandhi","sequence":"additional","affiliation":[{"name":"AbbVie, Florham Park, NJ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Ailani","sequence":"additional","affiliation":[{"name":"MedStar Georgetown University Hospital, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,2,27]]},"reference":[{"key":"bibr1-03331024241235156","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.800605"},{"key":"bibr2-03331024241235156","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","volume":"18","year":"2019","journal-title":"Lancet Neurol"},{"key":"bibr3-03331024241235156","doi-asserted-by":"publisher","DOI":"10.1111\/head.13459"},{"key":"bibr4-03331024241235156","unstructured":"International Headache Society. IHS classification ICHD-3: migraine, https:\/\/ichd-3.org\/1-migraine\/ (2019, accessed 28 February 2023)."},{"key":"bibr5-03331024241235156","doi-asserted-by":"publisher","DOI":"10.1111\/head.14153"},{"key":"bibr6-03331024241235156","first-page":"973","volume":"21","author":"Silberstein SD.","year":"2015","journal-title":"Continuum (Minneap Minn)"},{"key":"bibr7-03331024241235156","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182535d20"},{"key":"bibr8-03331024241235156","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11061656"},{"key":"bibr9-03331024241235156","unstructured":"AbbVie. Qulipta (package insert). Dublin, Ireland: AbbVie, 2023."},{"key":"bibr10-03331024241235156","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035908"},{"key":"bibr11-03331024241235156","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01049-8"},{"key":"bibr12-03331024241235156","unstructured":"Pfizer Inc. Nurtec ODT (package insert). New York, NY: Pfizer Inc. 2023."},{"key":"bibr13-03331024241235156","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32544-7"},{"key":"bibr14-03331024241235156","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30234-9"},{"key":"bibr15-03331024241235156","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31606-X"},{"key":"bibr16-03331024241235156","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811090"},{"key":"bibr17-03331024241235156","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.05.004"},{"key":"bibr18-03331024241235156","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413485658"},{"key":"bibr19-03331024241235156","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"bibr20-03331024241235156","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418758283"},{"key":"bibr21-03331024241235156","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2009.01852.x"},{"issue":"1","key":"bibr22-03331024241235156","first-page":"53","volume":"22","author":"Ailani J","year":"2022","journal-title":"J Headache Pain"},{"key":"bibr23-03331024241235156","unstructured":"Eli Lilly and Company. A study of galcanezumab (LY2951742) in adult participants with episodic migraine (CHALLENGE-MIG) NCT05127486, https:\/\/clinicaltrials.gov\/study\/NCT05127486 (2023, accessed 25 October 2023)."},{"key":"bibr24-03331024241235156","doi-asserted-by":"publisher","DOI":"10.1111\/head.14128"},{"key":"bibr25-03331024241235156","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231159366"},{"key":"bibr26-03331024241235156","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231152169"},{"key":"bibr27-03331024241235156","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.09.145"},{"key":"bibr28-03331024241235156","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02520-2"},{"key":"bibr29-03331024241235156","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705848"}],"container-title":["Cephalalgia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024241235156","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03331024241235156","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024241235156","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:46:13Z","timestamp":1777387573000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.sagepub.com\/doi\/10.1177\/03331024241235156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1177\/03331024241235156"],"URL":"https:\/\/doi.org\/10.1177\/03331024241235156","relation":{},"ISSN":["0333-1024","1468-2982"],"issn-type":[{"value":"0333-1024","type":"print"},{"value":"1468-2982","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]},"article-number":"03331024241235156"}}